Prof Heinz Ludwig speaks to ecancer at the 2019 MyKE Myeloma meeting in Barcelona about the main highlights from this year's meeting.
He discusses presentations about the relationship between MRD negativity and high-risk disease, imaging technologies used to diagnose multiple myeloma and the impact of neuropathy and bone disease.
Also, Prof Ludwig gives us an overview of the topics that were discussed in the second session, which included cardiac and renal implications that should be considered in multiple myeloma, the role of nurses in patient care and emerging immunotherapies for patients with multiple myeloma.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.